دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Issue Highlights page
doi : 10.1016/S0360-3016(21)02878-9
Volume 111, Issue 5, 1 December 2021, Pages A11-A12
Optimizing Organ Preservation Strategies in Localized Muscle Invasive Bladder Cancer
NuradhJosephMD, MRCP, FRCR*†
doi : 10.1016/j.ijrobp.2021.09.021
Volume 111, Issue 5, 1 December 2021, Pages 1097-1100
Right on the Nose: A Case of Locally Invasive Extranodal Lymphoma
Horatio R.ThomasMD, MMScSue S.YomMD, PhD
doi : 10.1016/j.ijrobp.2021.03.042
Volume 111, Issue 5, 1 December 2021, Pages 1101-1102
Short-Course Induction Chemotherapy Followed by Radiotherapy is the Effective Strategy for Intermediate-Risk/High-Risk Early-Stage ENKTCL
YongYangMD
doi : 10.1016/j.ijrobp.2021.09.043
Volume 111, Issue 5, 1 December 2021, Page 1103
Combined Modality Therapy in Extranodal NK/T Cell Lymphoma
Kheng-WeiYeohFang YueYong
doi : 10.1016/j.ijrobp.2021.09.044
Volume 111, Issue 5, 1 December 2021, Pages 1103-1105
SMILE and Beam On
Sarah A.MilgromMDBradley M.HaverkosMD
doi : 10.1016/j.ijrobp.2021.09.045
Volume 111, Issue 5, 1 December 2021, Page 1105
Chemoradiation to Improve Local Control, and Thereby Overall Survival for Limited Stage Nasal NKTCL
Susan Y.WuM.D.Chelsea C.PinnixM.D., Ph.D.
doi : 10.1016/j.ijrobp.2021.09.046
Volume 111, Issue 5, 1 December 2021, Pages 1105-1106
Ten Years, Hundreds of Editors, and Thousands of Manuscripts: Closing My Account at the Red Journal
AnthonyZietmanMD FASTRO(Editor-in-Chief)
doi : 10.1016/j.ijrobp.2021.08.028
Volume 111, Issue 5, 1 December 2021, Pages 1107-1109
Tribute to Anthony L. Zietman MD, FASTRO
Thomas J.EichlerMD
doi : 10.1016/j.ijrobp.2021.08.030
Volume 111, Issue 5, 1 December 2021, Page 1110
Promoting Gender Equity at the Red Journal: A Decade's Work
Shauna R.CampbellDO*Katherine E.BennettMA†Sue S.YomMD, PhD‡ReshmaJagsiMD, DPhil§
doi : 10.1016/j.ijrobp.2021.07.011
Volume 111, Issue 5, 1 December 2021, Pages 1111-1113
Reflections on Anthony Zietman From Gastrointestinal Cancer and Physics Editors
Gastrointestinal Cancer Editors: Christopher G.Willett?Daniel T.Chang†Brian G.Czito?Stanley L.Liauw‡Jennifer Y.Wo§Physics Editors: EricKlein?ZheChen¶David J.Carlson#Indrin J.Chetty??
doi : 10.1016/j.ijrobp.2021.09.007
Volume 111, Issue 5, 1 December 2021, Pages 1114-1117
Reflections of the Senior Editors for Biology
J. MartinBrownPhD*Michael L.FreemanPhD†BrianMarplesPhD‡MarjanBoermaPhD§
doi : 10.1016/j.ijrobp.2021.06.039
Volume 111, Issue 5, 1 December 2021, Pages 1118-1119
The Model of an ASTRO Servant Leader
Theodore L.DeWeeseMD*DavidBeyerMD†Leonard L.GundersonMD‡Bruce G.HafftyMD§Paul M.HarariMD?Colleen A.LawtonMD¶Bruce D.MinskyMD#Michael L.SteinbergMD??
doi : 10.1016/j.ijrobp.2021.08.014
Volume 111, Issue 5, 1 December 2021, Pages 1120-1121
A Portrait of the Artist as a Younger Man
Brian D.KavanaghMD, MPH, FASTRO
doi : 10.1016/j.ijrobp.2021.08.040
Volume 111, Issue 5, 1 December 2021, Page 1122
The Essential Anthony
Phillip M.DevlinMD, FACR, FASTRO, FFRRCSI, FABSHelen A.ShihMD, MS, MPH, FASTRO
doi : 10.1016/j.ijrobp.2021.09.001
Volume 111, Issue 5, 1 December 2021, Pages 1123-1124
Goodbye Anthony. Thank you for everything.
doi : 10.1016/j.ijrobp.2021.07.037
Volume 111, Issue 5, 1 December 2021, Page 1125
Overview and Lessons From the Preclinical Chemoradiotherapy Testing Consortium
Jeffrey C.BuchsbaumMD, PhD, AM, FASTROC. NormanColemanMD, FASTROEric J.BernhardPhDMichael G.EspeyPhDBhadrasainVikramMD, FASTRO
doi : 10.1016/j.ijrobp.2021.07.1709
Volume 111, Issue 5, 1 December 2021, Pages 1126-1130
Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations
Steven H.LinMD, PhD?HenningWillersMD†SunilKrishnanMD‡Jann N.SarkariaMD§MichaelBaumannMD||Theodore S.LawrenceMD, PhD¶
doi : 10.1016/j.ijrobp.2021.08.018
Volume 111, Issue 5, 1 December 2021, Pages 1131-1139
Regulatory Considerations in the Development of Radiation-Drug Combinations
Amanda J.WalkerMD
doi : 10.1016/j.ijrobp.2021.07.1710
Volume 111, Issue 5, 1 December 2021, Pages 1140-1144
High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers
RuiYeMPH*†YaweiQiaoMS*Pankaj K.SinghPhD‡YifanWangPhD*JianzhongHeBS*NanLiPhD*SunilKrishnanMD, PhD‡Steven H.LinMD, PhD*†
doi : 10.1016/j.ijrobp.2021.07.1712
Volume 111, Issue 5, 1 December 2021, Pages e27-e37
The combination of cytotoxic chemotherapy with radiation therapy (CRT) has resulted in significant improvements in clinical outcomes for patients with many locally advanced unresectable cancers. Only a small proportion of patients achieve pathologic complete responses to CRT; combination of CRT with targeted agents offers the promise of further improving treatment responses. However, numerous clinical trials have failed to show an improvement in clinical outcomes with the addition of targeted agents. To increase the accessibility of our screening method and accelerate the pace at which novel combinations with CRT are identified and incorporated into standard practices for treatments, we report details on screening method optimization, data generation, and downstream data analysis.
Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic
Leslie A.ParselsPhD*QiangZhangPhD*DavidKarnakPhD*Joshua D.ParselsBS*KwokLamPhD*HenningWillersMD†Michael D.GreenMD, PhD*AlnawazRehemtullaPhD*Theodore S.LawrenceMD, PhD*Meredith A.MorganPhD*
doi : 10.1016/j.ijrobp.2021.07.1708
Volume 111, Issue 5, 1 December 2021, Pages e38-e53
Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers
SonjaDragojevicPhD*JianxiongJiMD, PhD*†‡Pankaj K.SinghPhD§Margaret A.ConnorsBS?Robert W.MutterMD*Scott C.LesterMD*Surabhi M.TaleleMS?WenjuanZhangMS?Brett L.CarlsonBA?Nicholas B.RemmesPhD*Sean S.ParkMD, PhD*William F.ElmquistPharmD, PhD?SunilKrishnanMBBS, MD§Erik J.TryggestadPhD*Jann N.SarkariaMD*
doi : 10.1016/j.ijrobp.2021.08.003
Volume 111, Issue 5, 1 December 2021, Pages e54-e62
Screening and Validation of Molecular Targeted Radiosensitizers
HenningWillersMD?XiaoPanPhD?NathalieBorgeaudPhD†‡§IrinaKorovinaPhD†‡§||LydiaKoiPhD†||¶ReginaEganBS#PatriciaGreningerBA#AlizaRosenkranzBS?JongKungPhD?Andrew S.LissPhD??Leslie A.ParselsPhD††Meredith A.MorganPhD††Theodore S.LawrenceMD, PhD††Steven H.LinMD, PhD‡‡Theodore S.HongMD?Beow Y.YeapScD§§Lori J.WirthMD§§Aaron N.HataMD, PhD#…MechthildKrauseMD†‡§||¶¶¶
doi : 10.1016/j.ijrobp.2021.07.1694
Volume 111, Issue 5, 1 December 2021, Pages e63-e74
Accurate Dosimetry for Radiobiology
Larry A.DeWerdPhD, FAAPMKeithKunugiMBA, MS
doi : 10.1016/j.ijrobp.2021.09.002
Volume 111, Issue 5, 1 December 2021, Pages e75-e81
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy
Nicholas B.FiguraMD?Timothy J.RobinsonMD, PhD*†Austin J.SimMD, JD*XuefengWangPhD†BiweiCaoMS†Julio C.ChavezMD‡§Bijal D.ShahMD‡§FarhadKhimaniMD?AleksandrLazaryanMD, PhD?MarcoDavilaMD, PhD?ChristinaBachmeierPharmD, BCOP?TaigaNishihoriMD?Hien D.LiuMD?SungjuneKimMD, PhD*Frederick L.LockeMD?Michael D.JainMD, PhD?
doi : 10.1016/j.ijrobp.2021.06.038
Volume 111, Issue 5, 1 December 2021, Pages 1145-1154
Practice Patterns of Pediatric Total Body Irradiation Techniques: A Children's Oncology Group Survey
PremaRassiahPhD?NatiaEsiashviliMD†Arthur J.OlchPhD‡Chia-HoHuaPhD§KenUlinPhD?AndreaMolineuMS¶KarenMarcusMD#MaheshGopalakrishnanMS??SushaPillaiMS††NataliyaKovalchukPhD‡‡AnLiuPhD§§GregNiyazovMS??JosePeñagarícanoMD¶¶FredCheung##Adam C.OlsonMD???Cheng-ChiaWuMD†††Harish K.MalhotraPhD‡‡‡Iain J.MacEwanMD§§§JacquelineFaughtPhD§John C.BrenemanMD???David S.FollowillPhD¶Thomas J.FitzGeraldMD¶¶¶John A.KalapurakalMD??
doi : 10.1016/j.ijrobp.2021.07.1715
Volume 111, Issue 5, 1 December 2021, Pages 1155-1164
Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition
Elliot H.Akama-GarrenMSc?†Zachary S.MorrisMD, PhD‡Andrew G.SikoraMD, PhD§RalphWeichselbaumMD?#Jonathan D.SchoenfeldMD, MPH?†
doi : 10.1016/j.ijrobp.2021.08.009
Volume 111, Issue 5, 1 December 2021, Pages 1165-1175
Immune checkpoint inhibitors (ICIs) lead to durable responses in a subset of patients with cancer, but most patients do not respond to ICI, prompting interest in combining immunotherapy with other therapeutic regimens. Preclinical evidence supports the potential for therapeutic synergy between immunotherapy and radiation therapy through modulation of the tumor microenvironment and antitumor immune responses. Local therapy also has the potential to overcome localized sites of relative immune suppression and resistance. Prospective clinical trials have been initiated to test these hypotheses in the clinic as well as to investigate the toxicities and adverse events associated with combination immunotherapy and radiation therapy. In this review, we discuss the emerging results from prospective clinical trials of combination immunotherapy and radiation therapy, the safety and efficacy of their combination, concordance with preclinical and retrospective data, and some of the remaining open questions to be addressed by future clinical trials.
Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer
Matthew R.McFarlaneMD, PhD*Kimberly A.HochstedlerMS†Anna M.LaucisMD, MPhil?YilunSunPhD*AulinaChowdhuryBS‡Martha M.MatuszakPhD*JamesHaymanMD*DerekBergsmaMD§ThomasBoikeMD||LarryKestinMD||BenjaminMovsasMD¶IngaGrills#MichaelDominelloMD??Robert T.DessMD*CaitlinSchonewolfMD*Daniel E.SprattMD*LoriPierceMD*PeterPaximadisMD††ShrutiJollyMD*MatthewSchipperPhD*†on behalf of the
doi : 10.1016/j.ijrobp.2021.07.1691
Volume 111, Issue 5, 1 December 2021, Pages 1176-1185
Cost-Effectiveness of Prophylactic Cranial Irradiation Versus MRI Surveillance for Extensive-Stage Small Cell Lung Cancer
HayeonKimPhD, DABR*AndrewKellerMD?SushilBeriwalMD, MBA*Kenneth J.SmithMD, MS†John A.VargoMD?
doi : 10.1016/j.ijrobp.2021.04.049
Volume 111, Issue 5, 1 December 2021, Pages 1186-1194
Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial
GrantHarmonMD*DennisChanMD*BrianLeePhD*ChelseaMillerMD†AlexGorbonosMD‡GopalGuptaMD‡MarcusQuekMD‡MichaelWoodsMD‡BitalSavir-BaruchMD§Matthew M.HarkenriderMD*Abhishek A.SolankiMD, MS?
doi : 10.1016/j.ijrobp.2021.05.009
Volume 111, Issue 5, 1 December 2021, Pages 1195-1203
Impact of Pelvic Radiation Therapy for Prostate Cancer on Global Metabolic Profiles and Microbiota-Driven Gastrointestinal Late Side Effects: A Longitudinal Observational Study
Miguel R.FerreiraPhD*†‡§Caroline J.SandsPhD||Jia V.LiPhD¶Jervoise N.AndreyevPhD#ElenaChekmenevaPhD||SarahGullifordPhD*??JulianMarchesiPhD¶††Matthew R.LewisPhD||David P.DearnaleyFRCR*†
doi : 10.1016/j.ijrobp.2021.07.1713
Volume 111, Issue 5, 1 December 2021, Pages 1204-1213
Radiation therapy to the prostate and pelvic lymph nodes (PLNRT) is part of the curative treatment of high-risk prostate cancer. Yet, the broader influence of radiation therapy on patient physiology is poorly understood. We conducted comprehensive global metabolomic profiling of urine, plasma, and stools sampled from patients undergoing PLNRT for high-risk prostate cancer.
Radiation Toxicity in Patients With Collagen Vascular Disease: A Meta-Analysis of Case-Control Studies
Parvez M.ShaikhMD*Sarah A.SinghMD*FioriAliteMD†John A.VargoMD‡BahmanEmamiMD§Meng-JiaWuPhD§GeraldineJacobsonMD, MPH, MBA*VeliBakalovMD?WilliamSmallJrMD§BasemDahshanMD*JoshuaWeirDO*Paul B.RenzDO?Matthew M.HarkenriderMD§
doi : 10.1016/j.ijrobp.2021.08.006
Volume 111, Issue 5, 1 December 2021, Pages 1214-1226
Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study
JuneCorryMD?†Wai TongNgMD‡§AlishaMooreBMedRadSci?Horace C.W.ChoiPhD§QuynhLeMD¶SofeeHolmesBMedRadSci?ArieMunandarMD#ShengziWangMD??AngelaCamachoMD††JirapornSetakornnukulMD‡‡ChuleepornJiarpinitnunMD§§P.N.HiepMD??Sarbani GhoshLaskarMD¶¶NoureddineBenjaafarMD##MohammadFaheemFRCP???FengJinMD†††Chiraz Nasr BenAmmarMD‡‡‡RubinaAliMCPS§§§KadaBoualgaMD???SherifAbdelwahabMD¶¶¶KiattisaSommatFRCR###YunganTaoMD????BrianO'SullivanMD††††NancyLeeMD‡‡‡‡EduardoZubizarettaMD§§§§BenPrajogiMD§§§§KirstenHopkinsMD§§§§EduardoRosenblattMD§§§§Anne W.M.LeeMD????
doi : 10.1016/j.ijrobp.2021.08.013
Volume 111, Issue 5, 1 December 2021, Pages 1227-1236
Most new nasopharyngeal cancer cases occur in low-income and middle-income countries, and these patients experience poorer overall survival than that of new nasopharyngeal cancer cases in high-income countries. The goal of this research project is to determine whether the introduction of a radiation therapy quality assurance program can ultimately improve outcomes for nasopharyngeal cancer patients in lower-income and middle-income countries. This study reports the results of the first phase of the International Atomic Energy Agency Coordinated Research Project (325-E3-TM-47712).
Serum MicroRNAs as Xerostomia Biomarkers in Patients With Oropharyngeal Cancer Undergoing Radiation Therapy
Bart?omiejTomasikMD, PhD?†‡AnnaPapis-UbychMD§KonradStawiskiMD*JacekFijuthMD, PhD||PiotrK?dzierawskiMD, PhD¶#JacekSadowskiMD¶Rafa?StandoMD¶RobertBibikMD, PhD???ukaszGraczykMD??TomaszLatusekMD, PhD††TomaszRutkowskiMD, PhD‡‡WojciechFendlerMD, PhD?‡
doi : 10.1016/j.ijrobp.2021.07.008
Volume 111, Issue 5, 1 December 2021, Pages 1237-1249
Irradiation at Ultra-High (FLASH) Dose Rates Reduces Acute Normal Tissue Toxicity in the Mouse Gastrointestinal System
Jia-LingRuanPhD*CarlLeeMSc†ShariWoutersMSc‡§Iain D.C.TullisPhD*MiekeVerslegersPhD‡MohamedMysaraPhD‡Chee KinThenMSc*Sean C.SmartPhD*Mark A.HillPhD*Ruth J.MuschelPhD*Amato J.GiacciaPhD*BorivojVojnovicPhD*Anne E.KiltiePhD*KristofferPeterssonPhD*?
doi : 10.1016/j.ijrobp.2021.08.004
Volume 111, Issue 5, 1 December 2021, Pages 1250-1261
Fractionated Low-Dose Radiation Induces Long-Lasting Inflammatory Responses in the Hippocampal Stem Cell Niche
ZoéSchmalPhD*BenHammerMD*AndreasMüllerPhD†Claudia E.RübePhD, MD*
doi : 10.1016/j.ijrobp.2021.07.007
Volume 111, Issue 5, 1 December 2021, Pages 1262-1275
Synchrotron Microbeam Radiation Therapy for the Treatment of Lung Carcinoma: A Preclinical Study
VerdianaTrappettiMSc*CristianFernandez-PalomoPhD*LloydSmythPhD†MitziKleinVMD‡DavidHaberthürPhD*DuncanButlerPhD‡MicahBarnesMSc‡§NahokoShintaniPhD*Michaelde VeerPhD||Jean A.LaissueMD*Marie C.VozeninPhD¶ValentinDjonovMD*
doi : 10.1016/j.ijrobp.2021.07.1717
Volume 111, Issue 5, 1 December 2021, Pages 1276-1288
A Prospective Trial Demonstrating the Benefit of Personalized Selection Of Breath-Hold Technique for Upper-Abdominal Radiation Therapy Using the Active Breathing Coordinator
BrianaFarrugiaBAppSc?†KellieKnightHScD, MHlthSc, BAppSc†CarolineWrightPhD, MSc, PGCE, BSc(Hons), DCR(T)†MarkTaceyMBiostat, BSc?‡FarshadForoudiMBBS MPA DMedSc FRANZCR*MichaelChaoBBS DMedSc, FRANZCR, AFRACMA*RichardKhorMBBS, DMedSc, FRANZCR?§?
doi : 10.1016/j.ijrobp.2021.08.001
Volume 111, Issue 5, 1 December 2021, Pages 1289-1297
For upper abdominal tumors, our institutional-standard motion reduction method is the expiration breath-hold (EBH) technique, using Active Breathing Coordinator (ABC). However, an individual patient's breath-hold (BH) reproducibility (RBH) may be improved in deep inspiration or inspiration breath-hold (DIBH or IBH). This trial compared the tumor position RBH, stability (SBH), and breath-hold time (TBH) of 3 BH methods, using ABC, to personalize the selection of technique, by using a preplanning screening assessment.
Dosimetric Uncertainties Resulting From Interfractional Anatomic Variations for Patients Receiving Pancreas Stereotactic Body Radiation Therapy and Cone Beam Computed Tomography Image Guidance
Joshua S.NiedzielskiPhD*YufeiLiuMD†Sylvia S.W.NgMD, PhD†Rachael M.MartinPhD*Luis A.PerlesPhD*SamBeddarPhD*NealRebuenoCMD*Eugene J.KoayMD, PhD†CullenTaniguchiMD, PhD†Emma B.HollidayMD†PrajnanDasMD, MS†Grace L.SmithMD, PhD†Bruce D.MinskyMD†Ethan B.LudmirMD†Joseph M.HermanMD, MSc†AlbertKoongMD, PhD†Gabriel O.SawakuchiPhD*‡
doi : 10.1016/j.ijrobp.2021.08.002
Volume 111, Issue 5, 1 December 2021, Pages 1298-1309
To estimate the effects of interfractional anatomic changes on dose to organs at risk (OARs) and tumors, as measured with cone beam computed tomography (CBCT) image guidance for pancreatic stereotactic body radiation therapy.
Quantitative Bioluminescence Tomography-Guided Conformal Irradiation for Preclinical Radiation Research
XiangkunXuPhD?†aZijianDengPhD?†aHamidDehghaniPhD‡IulianIordachitaPhD§MichaelLimMD?||John W.WongPhD*Ken Kang-HsinWangPhD?†
doi : 10.1016/j.ijrobp.2021.08.010
Volume 111, Issue 5, 1 December 2021, Pages 1310-1321
In Regard to de Groot et al.
GulerYavasMD1CagdasYavasMD1CemOnalMD12
doi : 10.1016/j.ijrobp.2021.08.011
Volume 111, Issue 5, 1 December 2021, Page 1322
In Reply to Yavas et al.
CrystalGrootMD12Jannet C.BeukemaMD3Niek J.H.PrakkenPhD4Christina T.MuijsPhD5
doi : 10.1016/j.ijrobp.2021.08.012
Volume 111, Issue 5, 1 December 2021, Page 1323
MC1675, a Phase III Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) vs. Standard Adjuvant Treatment for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma
D.M.Ma1K.Price2E.J.Moore3S.H.Patel4M.L.Hinni5B.Fruth6N.R.Foster6K.Van Abel3L.X.Yin3M.A.Neben-Wittich1L.A.McGee7J.C.Rwigema8D.M.Routman9S.C.Lester9D.L.Price3J.R.Janus10J.L.Kasperbauer11T.H.Nagel5A.V.Chintakuntlawar12P.Savvides13J.J.Garcia14R.L.Foote9
doi : 10.1016/j.ijrobp.2021.09.012
Volume 111, Issue 5, 1 December 2021, Page 1324
A Randomized Trial of Radiotherapy vs. Trans-Oral Surgery for Treatment De-Escalation in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (ORATOR2)
D.A.Palma1E.Prisman2E.Berthelet3E.Tran4S.N.Hamilton5J.Wu3A.Eskander6K.Higgins6I.Karam7I.Poon8Z.A.Husain8D.Enepekides6M.Hier9K.Sultanem9K.Richardson10A.Mlynarek10S.Johnson-Obaseki11L.Eapen12M.Odell11A.J.Bayley13S.Dowthwaite14J.E.Jackson14M.Dzienis14J.O'Neil14S.Chandarana15R.N.Banerjee16R.Hart15J.Chung17T.C.Tenenholz17S.Krishnan18H.V.Le19J.Yoo20A.Mendez20E.Winquist21S.Kuruvilla21P.Stewart22A.Warner1S.Mitchell23J.Chen24C.Parker25B.Wehrli26K.Kwan26J.Theurer27J.Sathya22J.A.Hammond28N.E.Read23V.M.Venkatesan22D.MacNeil20K.Fung25A.Nichols29
doi : 10.1016/j.ijrobp.2021.09.013
Volume 111, Issue 5, 1 December 2021, Pages 1324-1325
Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ? Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast
C.J.Tsai1J.T.Yang1D.M.Guttmann1N.Shaverdian1A.F.Shepherd1J.Eng2D.Gelblum1A.J.Xu1A.Namakydoust2A.Iqbal2J.M.Mann1I.Preeshagul2C.Hajj1E.F.Gillespie1S.Sugarman2S.Modi2C.Dang2P.Drullinsky2R.Yeh3J.Girshman3J.Das3W.Zhi2Q.LaPlant1M.Reyngold1A.Rimner1J.Y.Shin1A.J.Wu1K.Ng2A.Gucalp2R.Sanford2A.J.Khan1J.Bromberg2A.D.Seidman2E.Comen2T.A.Traina2D.R.Gomez1Z.Zhang4M.E.Robson2C.M.Rudin2S.N.Powell1
doi : 10.1016/j.ijrobp.2021.09.014
Volume 111, Issue 5, 1 December 2021, Pages 1325-1326
